Written by Lidia Dinkova on September 17, 2014

A partnership between University of Miami researchers and a Georgia-based biomedical company this month made a new type of stem cell commercially available for bone regeneration and healing.

The marrow-isolated adult multi-lineage inducible cell, known as the MIAMI cell, is the result of 15 years of research by the University of Miami.

Since the stem cell was made commercially available, about 21 patients have been treated with a MIAMI cell infusion.

We are controlling the release to make sure it goes very smoothly, said Tracy S. Anderson, president and CEO of Vivex Biomedical Inc.

Vivex invested in the research and development of the cell and licensed the technology from UM for orthopedic use. The company has contracted with the universitys tissue bank to develop the cell for commercial use and pays an undisclosed royalty back to UM from sales.

Before the MIAMI cell goes to full national release in January 2015, Vivex is controlling the use of the cell.

I am going very slowly and selectively with the surgeons we are working with, Mr. Anderson said. Anytime you have a new product like this, you have to make sure that it goes smoothly.

Mr. Anderson didnt want to disclose revenue generated from the sale of the MIAMI cell, only saying that it has been significant.

So far, the MIAMI cell has been used in bone regeneration and healing in Utah, Florida, Georgia, Michigan, Illinois and Ohio.

Read this article:
21 infused with new UM stem cell